Physician profile
Robert Sullivan
NPI 1952455909
$5,428.44
in general payments reported to CMS, 2019-2025
34 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $15.97 · 2021: $221 · 2022: $494 · 2023: $914 · 2024: $2,004 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,435 · Education: $54.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,434.65 |
| Education | $54.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $717.67 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $610.43 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $610.06 | 2019-2025 | Jynarque, Voyxact |
| Ani Pharmaceuticals, INC. | $524.52 | 2022-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $505.40 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $341.05 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $244.72 | 2023-2025 | |
| Amgen INC. | $202.18 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $201.81 | 2021-2024 | |
| Vifor Pharma, INC. | $191.89 | 2020-2025 | Veltassa |
| Ardelyx, INC. | $174.54 | 2023-2025 | Ibsrela |
| Vantive US Healthcare LLC | $140.80 | 2025 | Renal - Pd |
| Mallinckrodt Enterprises LLC | $128.84 | 2019 | |
| Mallinckrodt Hospital Products INC. | $104.18 | 2025 | Terlivaz, Acthar |
| Akebia Therapeutics INC | $92.63 | 2022-2025 | Auryxia, Vafseo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $77.48 | 2022-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.68 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $60.90 | 2022-2024 | Givlaari |
| Opko Pharmaceuticals, LLC | $54.27 | 2023 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $45.81 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $42.80 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.96 | 2021-2023 | Gattex |
| Smith+Nephew, INC. | $33.07 | 2024 | Oasis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.07 | 2025 | Voyxact |
| Kyowa Kirin, INC. | $23.93 | 2024 | Crysvita |
| Cardinal Health 200 LLC | $22.48 | 2021 | |
| Cordis US Corp. | $21.28 | 2022 | |
| Renalytix Ai, INC. | $19.72 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Horizon Therapeutics Plc | $18.76 | 2023 | Krystexxa |
| Shield Therapeutics INC | $18.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.18 | 2021 | |
| Glaxosmithkline, LLC. | $17.09 | 2024 | Jesduvroq, Benlysta |
| Baxter Healthcare | $15.91 | 2024 | Renal - Pd |
| Corcept Therapeutics | $15.87 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.